| scholarly article | Q13442814 |
| P2093 | author name string | Neil Johnson | |
| Jeffrey D Parvin | |||
| Alan D D'Andrea | |||
| Richard D Kennedy | |||
| Geoffrey I Shapiro | |||
| Shailja Pathania | |||
| Yu-Chen Li | |||
| Mansi Arora | |||
| Dongpo Cai | |||
| P2860 | cites work | BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage | Q24292278 |
| Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis | Q24515107 | ||
| BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site | Q24554478 | ||
| Human CtIP promotes DNA end resection | Q24646062 | ||
| DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1 | Q27938100 | ||
| Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway | Q28203777 | ||
| Association of BRCA1 with Rad51 in mitotic and meiotic cells | Q28302118 | ||
| ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks | Q29614215 | ||
| Chk1 and Chk2 kinases in checkpoint control and cancer | Q29617706 | ||
| Cell cycle checkpoint signaling through the ATM and ATR kinases | Q29617837 | ||
| Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage | Q29619360 | ||
| Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1 | Q30477585 | ||
| BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number | Q37515419 | ||
| A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein | Q39758925 | ||
| Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. | Q40028909 | ||
| Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells | Q40230424 | ||
| Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers | Q40243253 | ||
| Unmasking the redundancy between Cdk1 and Cdk2 at G2 phase in human cancer cell lines | Q40281425 | ||
| AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. | Q40333056 | ||
| BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants | Q40333192 | ||
| Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. | Q40459672 | ||
| BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis | Q40626126 | ||
| Cdk1 is sufficient to drive the mammalian cell cycle | Q41791627 | ||
| Mouse Brca1: localization sequence analysis and identification of evolutionarily conserved domains | Q48068725 | ||
| In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) | Q78516462 | ||
| P433 | issue | 3 | |
| P921 | main subject | DNA damage | Q5205747 |
| P304 | page(s) | 327-339 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | Molecular Cell | Q3319468 |
| P1476 | title | Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage | |
| P478 | volume | 35 |
| Q38324762 | A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition |
| Q41881917 | A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin |
| Q36941509 | ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation |
| Q28488177 | ATM-dependent MiR-335 targets CtIP and modulates the DNA damage response |
| Q37580261 | Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer |
| Q37875377 | Beyond ATM: the protein kinase landscape of the DNA damage response |
| Q90472180 | CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner |
| Q47112337 | CDK1 promotes nascent DNA synthesis and induces resistance of cancer cells to DNA-damaging therapeutic agents |
| Q42371594 | Cell cycle specific radiosensitisation by the disulfiram and copper complex |
| Q26752319 | Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway |
| Q39330291 | Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1. |
| Q35737613 | Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. |
| Q38909532 | Cyclin E as a potential therapeutic target in high grade serous ovarian cancer |
| Q24561485 | Cyclin-dependent kinase inhibitor therapy for hematologic malignancies |
| Q37798827 | Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors |
| Q35608458 | DNA damage response and repair: insights into strategies for radiation sensitization of gliomas |
| Q35371237 | DNA damage response is suppressed by the high cyclin-dependent kinase 1 activity in mitotic mammalian cells |
| Q35900578 | Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy |
| Q45346807 | Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination |
| Q38750997 | Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma |
| Q90469263 | Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition |
| Q37984197 | Inhibiting homologous recombination for cancer therapy |
| Q39417419 | Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. |
| Q39125016 | Inhibitors of cyclin-dependent kinases as cancer therapeutics |
| Q64389066 | Kub5-Hera Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers |
| Q36796448 | Mammalian interphase cdks: dispensable master regulators of the cell cycle |
| Q33968055 | Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. |
| Q33754568 | PI 3 kinase related kinases-independent proteolysis of BRCA1 regulates Rad51 recruitment during genotoxic stress in human cells |
| Q88392173 | Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models |
| Q36771791 | Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks |
| Q33630829 | Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells |
| Q38137764 | Predictive biomarkers for cancer therapy with PARP inhibitors. |
| Q63965509 | Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality |
| Q35574807 | R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair |
| Q36280683 | Radiation-induced double-strand breaks require ATM but not Artemis for homologous recombination during S-phase |
| Q39716932 | Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1. |
| Q42010293 | Residual Cdk1/2 activity after DNA damage promotes senescence. |
| Q37611723 | Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System |
| Q34539316 | S100A11 plays a role in homologous recombination and genome maintenance by influencing the persistence of RAD51 in DNA repair foci |
| Q92864350 | SIRT6 coordinates with CHD4 to promote chromatin relaxation and DNA repair |
| Q24600363 | STRUCTURE-FUNCTION OF THE TUMOR SUPPRESSOR BRCA1 |
| Q53692325 | Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. |
| Q92724519 | Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition |
| Q35334436 | Targeting cell cycle regulators in hematologic malignancies. |
| Q38184667 | Targeting homologous recombination-mediated DNA repair in cancer |
| Q92825428 | Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death |
| Q38037329 | The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance |
| Q41292927 | The plant-specific CDKB1-CYCB1 complex mediates homologous recombination repair in Arabidopsis |
| Q36853236 | Therapeutic applications of PARP inhibitors: anticancer therapy and beyond |
| Q37474898 | Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair |
| Q37396839 | Wee1 kinase as a target for cancer therapy |
Search more.